Rothman KJ, Michels KB.
The continuing unethical use of placebo controls. N Engl J Med. 1994; 331:394.-8CrossRef
Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med. 2000; 133:455.-63
Leber PD. Hazards of inference: the active control investigation. Epilepsia. 1989; 30:Suppl 1S57.-63
Detre T. Ethical dilemmas in clinical research. Psychopharmacol Bull. 1996; 32:15.-7
Friend WC, Weijer C. Re: CCNP position paper on the use of placebos in psychiatry [Letter]. J Psychiatry Neurosci. 1996; 21:354.-6
Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ. 1991; 303:685.-92
Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000; 57:311.-7
Baldessarini RJ, Jamison KR. Effects of medical interventions on suicidal behavior. Summary and conclusions. J Clin Psychiatry. 1999; 60:Suppl 2117.-22
Lieberman JA. Ethical dilemmas in clinical research with human subjects: an investigator's perspective. Psychopharmacol Bull. 1996; 32:19.-25
Henn FA, Lader M. Medication-free research with schizophrenic patients. A European perspective. Arch Gen Psychiatry. 1997; 54:412.-3
Fins JJ, Miller FG. The call of the sirens. Navigating the ethics of medication-free research in schizophrenia. Arch Gen Psychiatry. 1997; 54:415.-6
Appelbaum PS. Drug-free research in schizophrenia: an overview of the controversy. IRB. 1996; 18:1.-5
Carpenter WT Jr, Schooler NR, Kane JM. The rational and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry. 1997; 54:401.-7
Depression in Primary Care: Volume 2. Treatment of Major Depression. Rockville, MD: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication no. 93-0551.
Research Involving Persons with Mental Disorders That May Affect Decision-Making Capacity. Volume I: Report and Recommendations of the National Bioethics Advisory Commission. Rockville, MD: National Bioethics Advisory Commission; 1998.
Perez-Stable EJ, Coates TJ, Baron RB, Biro BS, Hauck WW, McHenry KS, et al.. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension. J Gen Intern Med. 1995; 10:419.-28
. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995; 333:1581.-7
Consensus Conference on Medical Management of Stroke, held in the College on 26–27 May 1998. Proceedings of the Royal College of Physicians of Edinburgh. 1998;28:367-9.
Bath P. Alteplase not yet proven for acute ischaemic stroke. Lancet. 1998; 352:1238.-9
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al.. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352:1245.-51
Sherman DG. Defibrinogenation with Vipronex (Ancrod) for the treatment of acute, ischemic stroke. STAT Writers Group [Abstract]. Stroke. 1999; 30:234.
Furlan AJ, Higashida R, Wechsler L, Schulz G. PROACT II: recombinant prourokinase (r-ProUK) in acute cerebral thromboembolism. Initial trial results. PROACT II Investigators [Abstract]. Stroke. 1999; 30:234.
Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al.. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352:1413.-8
Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al.. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352:1407.-12
Guidance for industry: FDA approval of new cancer treatment uses for marketed drug and biological products. Rockville, MD: U.S. Food and Drug Administration; 1999.
. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet. 1994; 343:871.-81
Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al.. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer that 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990; 322:941.-9
Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al.. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990; 112:727.-37
Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al.. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertusse Working Group. N Engl J Med. 1996; 334:341.-8
Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996; 334:349.-55
. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989; 321:406.-12
. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525.-33
Bickell WH, Wall MJ Jr, Pepe PE, Martin RR, Ginger VF, Allen MK, et al.. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med. 1994; 331:1105.-9
Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmissions of the human immunodeficiency virus in developing countries. N Engl J Med. 1997; 337:853.-6
Angell M. The ethics of clinical research in the Third World [Editorial]. N Engl J Med. 1997; 337:847.-9
Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med. 1997; 337:1003.-5
Perinatal HIV Intervention Research in Developing Countries Workshop participants. Science, ethics, and the future of research into maternal infant transmission of HIV-1. Lancet. 1999; 353:832.-5
Halsey NA, Sommer A, Henderson DA, Black RE. Ethics and international research [Editorial]. BMJ. 1997; 315:965.-6
Christakis NA, Lynn LA, Castelo A. Clinical AIDS research that evaluates cost effectiveness in the developing world. IRB. 1991; 31:6.-8
Abdool Karim SS. Placebo controls in HIV perinatal transmission trials: a South African's viewpoint. Am J Public Health. 1998; 88:564.-6
Stein CM, Pincus T. Placebo-controlled studies in rheumatoid arthritis: ethical issues. Lancet. 1999; 353:400.-3
Guidance for industry: clinical development programs for drugs, devices and biological products for the treatment of rheumatoid drugs, devices and biological products for the treatment of rheumatoid arthritis (RA). Rockville, MD: U.S. Food and Drug Administration; 1999.
Brody BA. When are placebo-controlled trials no longer appropriate? Control Clin Trials. 1997; 18:602.-12
Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med. 1999; 341:531.-4